Literature DB >> 22370939

Multiple variants of TERT and CLPTM1L constitute risk factors for lung adenocarcinoma.

X F Chen1, S Cai, Q G Chen, Z H Ni, J H Tang, D W Xu, X B Wang.   

Abstract

Recent studies have shown that 5p15.33 is one of the chromosomal regions that is most consistently altered in lung cancer; common variants that are located in this region have been genotyped in various populations. However, the genetic contribution of these variants to carcinogenesis is relatively unknown. A clinic-based case-control study in Shanghai was undertaken on 196 patients with lung cancer and 229 healthy individuals. TERT rs2736100 and CLPTM1L rs401681 and rs402710 were genotyped using the ABI TaqMan Allelic Discrimination assay. For rs2736100, the G variant and the GG genotype were more frequent, whereas the TT genotype was less frequent in patients with lung adenocarcinoma than in controls. The CT genotype at rs401681 was more common and the TT genotype was rare in patients, and the differences were significant between lung adenocarcinoma patients and controls. This was also true for rs402710. Moreover, the frequency of the GGCTCT haplotype was higher and the TTTTTT frequency was lower in patients, especially those with lung adenocarcinoma. Aberrant linkage disequilibrium among the three SNPs was found in patients with lung adenocarcinoma. We conclude that multiple variants at 5p15.33 contribute to susceptibility to lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22370939     DOI: 10.4238/2012.February.16.2

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  30 in total

1.  CRR9p polymorphism as a protective factor for lung cancer.

Authors:  Yang Chen; Zhiguo Yu; Bo Zhang; Zhengqi Chang; Hong Wang; Zhandi Liu
Journal:  Tumour Biol       Date:  2014-06-24

2.  Quantitative assessment of common genetic variants on chromosome 5p15 and lung cancer risk.

Authors:  Hongyu Wu; Ren Zhu
Journal:  Tumour Biol       Date:  2014-03-12

3.  TERT rs2736100 polymorphism contributes to lung cancer risk: a meta-analysis including 49,869 cases and 73,464 controls.

Authors:  Wei Nie; Yuansheng Zang; Jiquan Chen; Qingyu Xiu
Journal:  Tumour Biol       Date:  2014-02-18

4.  Association between CLPTM1L polymorphisms (rs402710 and rs401681) and lung cancer susceptibility: evidence from 27 case-control studies.

Authors:  De-ping Zhao; Chen-lu Yang; Xiao Zhou; Jia-an Ding; Ge-ning Jiang
Journal:  Mol Genet Genomics       Date:  2014-06-07       Impact factor: 3.291

5.  Genetic polymorphisms of TERT and CLPTM1L and risk of lung cancer: a case-control study in northeast Chinese male population.

Authors:  Yue Zhang; Mengmeng Zhao; Li Shen; Yangwu Ren; Lingyan Su; Xuelian Li; Zhihua Yin; Baosen Zhou
Journal:  Med Oncol       Date:  2014-05-27       Impact factor: 3.064

6.  CLPTM1L gene rs402710 (C > T) and rs401681 (C > T) polymorphisms associate with decreased cancer risk: a meta-analysis.

Authors:  Jianzhou Tang; Changming Hu; Hua Mei; Liang Peng; Hui Li
Journal:  Oncotarget       Date:  2017-11-01

7.  Association between TERT rs2736100 polymorphism and lung cancer susceptibility: evidence from 22 case-control studies.

Authors:  Yunfeng Yuan; Chunlai Lu; Liang Xue; Di Ge
Journal:  Tumour Biol       Date:  2014-01-04

8.  CLPTM1L polymorphism as a protective factor for lung cancer: a case-control study in southern Chinese population.

Authors:  Tianbo Jin; Bin Li; Na He; Yao Zhang; Ridong Xia; Longli Kang; Yipeng Ding; Dongya Yuan
Journal:  Tumour Biol       Date:  2016-02-06

Review 9.  TERT genetic polymorphism rs2736100 was associated with lung cancer: a meta-analysis based on 14,492 subjects.

Authors:  Hui-Min Wang; Xue-Yan Zhang; Bo Jin
Journal:  Genet Test Mol Biomarkers       Date:  2013-12

10.  CRR9/CLPTM1L regulates cell survival signaling and is required for Ras transformation and lung tumorigenesis.

Authors:  Michael A James; Haris G Vikis; Everett Tate; Amy L Rymaszewski; Ming You
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.